Enliven Therapeutics Upsized Public Offering at $37.50/sh, Shares Surge 14.3%

By Bobby Samwell • Saturday, June 13 16:06 • Permanent Link

Enliven Therapeutics priced its upsized public offering at $37.50 a share, setting the size at 8,933,334 common shares and 1,733,333 pre-funded warrants.

The company expects gross proceeds of about $400.0 million before underwriting discounts, commissions and other expenses. The pre-funded warrants were priced at $37.499 each, just $0.001 below the common stock offering price.

Enliven also gave underwriters a 30-day option to buy up to 1,600,000 additional shares at the public offering price, less underwriting discounts and commissions.

The deal was announced June 11, 2026 and is expected to close on or about June 15, 2026. All of the shares and warrants are being sold by Enliven. The market has reacted to these announcements by moving the company's shares 14.3% to a price of $46.13. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.